Drug Profile
Ravagalimab - Abbvie
Alternative Names: ABBV 323; PR 1629977Latest Information Update: 11 Feb 2022
Price :
$50
*
At a glance
- Originator AbbVie
- Class Anti-inflammatories
- Mechanism of Action CD40 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Sjogren's syndrome; Ulcerative colitis
- Discontinued Crohn's disease
Most Recent Events
- 01 Feb 2022 AbbVie withdraws prior to enrolment a phase IIa trial in Sjogren's syndrome (In adults, In the elderly) in Netherlands (SC, Injection) (IV, Injection) (EudraCT2019-003131-31) (NCT05217472)
- 10 Jan 2022 AbbVie completes a phase II trial in Ulcerative Colitis(Treatment-experienced) in Canada, France, Germany, Hungary, Italy, the Netherlands, South Korea, Spain, USA and the UK (NCT03695185) (EudraCT2018-000930-37)
- 01 Jul 2021 AbbVie discontinues phase IIa trial in Sjogren's syndrome (In adults, In the elderly) in Netherlands (SC, Infusion) (IV, Infusion) (SC, Injection) (IV, Injection) (EudraCT2019-003131-31)